S. 331 (119th)Bill Overview

HALT Fentanyl Act

Crime and Law Enforcement|Administrative law and regulatory proceduresCrime and Law Enforcement
Cosponsors
Support
Republican
Introduced
Jan 30, 2025
Discussions
Bill Text
Current stageLaw

Became Public Law No: 119-26.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

The HALT Fentanyl Act adds a class-wide definition of “fentanyl-related substances” to Schedule I of the Controlled Substances Act, criminalizing substances that meet specified structural criteria unless already scheduled or exempt. It creates expedited, notice-based procedures and other flexibilities to allow researchers and certain institutions to study Schedule I substances, allows limited manufacturing incidental to research, requires Attorney General rulemaking within six months, tightens penalties and import/export provisions to cover fentanyl-related substances, and directs an Inspector General study on fentanyl research.

Why people may split

Progressives stress research and civil-liberty risks from class scheduling

Watch point

Relative to its intended legislative type, this bill is a substantive statutory modification that is generally well-specified in statutory language and operational detail but omits explicit fiscal resourcing and comprehensive long-term oversight measures.

The HALT Fentanyl Act adds a class-wide definition of “fentanyl-related substances” to Schedule I of the Controlled Substances Act, criminalizing substances that meet specified structural criteria unless already scheduled or exempt.

It creates expedited, notice-based procedures and other flexibilities to allow researchers and certain institutions to study Schedule I substances, allows limited manufacturing incidental to research, requires Attorney General rulemaking within six months, tightens penalties and import/export provisions to cover fentanyl-related substances, and directs an Inspector General study on fentanyl research.

Passage45/100

Substantive but targeted measure addressing a salient drug threat; research-friendly fixes improve buy-in, but broad class scheduling and interim rule authority raise legal and stakeholder pushback.

CredibilityPartially aligned

Relative to its intended legislative type, this bill is a substantive statutory modification that is generally well-specified in statutory language and operational detail but omits explicit fiscal resourcing and comprehensive long-term oversight measures.

Contention65/100

Progressives stress research and civil-liberty risks from class scheduling

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Federal agenciesLikely burdened

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • Potential benefitClass scheduling may reduce the rapid emergence of new illicit fentanyl analogs used in trafficking.
  • Potential benefitBroader Schedule I coverage simplifies prosecutorial and interdiction efforts against chemically modified fentanyl prod…
  • Federal agenciesExpedited research registration speeds federally funded or FDA investigational studies involving fentanyl substances.
Likely burdened
  • Potential burdenA broad structural definition risks criminalizing novel compounds with legitimate scientific or medical research potent…
  • Potential burdenExpanded Schedule I coverage may chill private-sector pharmaceutical development of fentanyl-related therapeutics.
  • Potential burdenAmbiguities in the chemical definition could cause enforcement errors and increased litigation over classifications.
03 · Why people split

Why the argument around this bill splits.

Progressives stress research and civil-liberty risks from class scheduling
Progressive40%

Supportive of strong action against illicit fentanyl trafficking, but worried the class-wide Schedule I approach is overbroad and will harm research and public-health responses.

The bill’s research-expedited provisions are helpful but may not fully mitigate risks to legitimate scientific work, harm reduction, or equitable enforcement.

Would press for monitoring and safeguards to protect medical research and civil liberties.

Split reaction
Centrist70%

Views the bill as a pragmatic attempt to stop rapidly evolving fentanyl analogs while also streamlining certain research barriers.

Sees value in expedited researcher registration and transparency requirements but wants careful, timely rulemaking and oversight to avoid unintended research or civil-liberty impacts.

Likely to support with technical fixes and monitoring.

Leans supportive
Conservative90%

Strongly favors the bill’s class-wide scheduling and tougher import/export and penalty language as necessary tools to halt fentanyl trafficking and deaths.

Sees the research facilitation as reasonable and subordinate to public-safety priorities.

Would prioritize enforcement and rapid implementation of rules.

Leans supportive
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Reached or meaningfully advanced

President

Reached or meaningfully advanced

Law

Reached or meaningfully advanced

Passage likelihood45/100

Substantive but targeted measure addressing a salient drug threat; research-friendly fixes improve buy-in, but broad class scheduling and interim rule authority raise legal and stakeholder pushback.

Scope and complexity
52%
Scopemoderate
52%
Complexitymedium
Why this could stall
  • Judicial challenges to class-wide definition vagueness
  • DEA/AG capacity to implement interim rules quickly
05 · Recent votes

Recent votes on the bill.

HOUSE · Jun 12, 2025
Final passage✓ PassedBipartisan

The House passed this bill. It now goes to the other chamber, and eventually to the President for signature.

What is a final passage?

The final vote on whether the bill becomes law (pending the other chamber and the President).

Yes 76% No 24%
Showing a quick cross-section of legislators, with followed members first when available.
SENATE · Mar 14, 2025
Final passage✓ PassedBipartisan

The Senate passed this bill. It now goes to the other chamber, and eventually to the President for signature.

What is a final passage?

The final vote on whether the bill becomes law (pending the other chamber and the President).

Yes 84% No 16%
Showing a quick cross-section of legislators, with followed members first when available.
SENATE · Mar 13, 2025
End debate✓ PassedBipartisan
60 votes required (3/5 of Senate)

The Senate voted to end debate. The bill can now move toward a final passage vote.

What is a end debate?

Cloture ends a filibuster and limits further debate. Requires 60 votes in the Senate.

Yes 85% No 15%
Showing a quick cross-section of legislators, with followed members first when available.
06 · Go deeper

Go deeper than the headline read.

Included on this page

Progressives stress research and civil-liberty risks from class scheduling

Substantive but targeted measure addressing a salient drug threat; research-friendly fixes improve buy-in, but broad class scheduling and i…

Unlocked analysis

Relative to its intended legislative type, this bill is a substantive statutory modification that is generally well-specified in statutory language and operational detail but omits explicit fiscal resourcing and compreh…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis